BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Designated as PMIBCR/Abl-R6, this is a peptide PROTAC capable of degrading Bcr/Abl, a protein of great importance in Philadelphia chromosome-positive chronic myeloid leukemia (LK-Ph+), which is an abnormal chromosome that leads to the increased expression of the Bcr/Abl fusion protein, which is related to 95% of chronic myeloid leukemia (CML) and 20% of acute lymphoblastic leukemia (ALL) cases [74,75].